TAIPEI, July 7, 2026 /PRNewswire/ -- Sports technology innovator VITBIO has announced the launch of OmniGmot AI Golfer, the world's first integrated golf biomechanics system to combine full-body AI motion capture with comprehensive plantar pressure analysis in a single wearable solution. Developed entirely with VITBIO's proprietary patented technologies, the system delivers laboratory-grade biomechanics insights directly on the golf course.
To showcase its real-world performance, VITBIO will welcome Spanish professional golfer Juan Salama, a former No. 1 ranked golfer in Spain, for live demonstrations during SPORTEC Tokyo from July 8–10 at Tokyo Big Sight. Salama will demonstrate how OmniGmot AI Golfer enables elite players to rapidly adapt to unfamiliar courses, optimize swing mechanics, and improve competitive performance using real-time AI-driven analysis.
Traditionally, golfers have relied on separate indoor motion capture systems and stationary force plates, making comprehensive biomechanics analysis impractical during actual play. OmniGmot AI Golfer eliminates this limitation by seamlessly integrating wearable AI smart insoles with full-body motion sensing, synchronizing ground reaction force, movement patterns, and swing mechanics through VITBIO's proprietary AI algorithms.
The system has been recognized by the Global Sports Innovation Center (GSIC), powered by Microsoft, and received the prestigious 2025 ISPO Product & Service Award, highlighting its innovation and impact on sports technology.
"OmniGmot AI Golfer gives my coach and me a completely new level of performance insight," said Juan Salama. "By combining foot pressure, movement patterns, and full-body motion analysis in real time, we can quickly understand how subtle weight shifts influence ball contact and make immediate adjustments when competing on unfamiliar courses."
Key innovations include:
- The world's first integrated AI system combining full-body motion capture with dynamic plantar pressure tracking.
- Outdoor-ready wearable technology that delivers accurate biomechanics data in real playing conditions.
- AI-powered pre-round analysis that builds a course-specific swing optimization model within minutes, helping golfers adapt quickly before competition.
VITBIO's integrated AI platform represents a significant advancement in wearable sports biomechanics and has already been invited for technical evaluation in international professional tournaments.
Visit VITBIO at Booth E1-6-5 during SPORTEC Tokyo, July 8–10, to experience the next generation of AI-powered golf performance technology.
About VITBIO
VITBIO is a pioneer in wearable sports technology, specializing in AI-powered biomechanics solutions developed through proprietary patented innovations. The company is dedicated to advancing athletic performance with intelligent wearable technologies that empower golfers and athletes worldwide.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
VITBIO Unveils the World's First AI Golf Training System Combining Full-Body Motion Capture and Plantar Pressure Analysis
A blood-based cancer screening technology developed in Asia is gaining international attention after real-world data from more than 84,145 individuals were presented at ASCO Breakthrough 2026 and highlighted by the American Society of Clinical Oncology. For Gene Solutions, this milestone underscores the growing global relevance of Asia-led multi-cancer detection innovation.
SINGAPORE, July 7, 2026 /PRNewswire/ -- Gene Solutions, a biotechnology company advancing genomic solutions for cancer detection and precision oncology, today announced a major global milestone for SPOT-MAS 10, its AI-powered, multi-omic blood-based test for multi-cancer screening.
Following its presentation at ASCO Breakthrough 2026 in Singapore, SPOT-MAS 10 clinical data have gained international attention through several key milestones: the presentation of a large-scale real-world study involving more than 84,145 asymptomatic individuals, recognition by the American Society of Clinical Oncology (ASCO) Press Center, coverage in ASCO's Science in Seconds, and the recent granting of U.S. FDA Breakthrough Device Designation.
The achievement reflects Gene Solutions' expanding global footprint. Bloomberg recently reported that the company is preparing for a potential Hong Kong IPO to support international growth, signaling increasing investor confidence in Asia-originated genomic technologies.
Large-Scale Asian Real-World Evidence Presented at ASCO Breakthrough 2026
The study, titled "Real-world performance of a multimodal cell-free DNA multi-cancer early detection test in Asian populations," evaluated SPOT-MAS in 84,145 asymptomatic individuals across Singapore, Thailand, Indonesia, the Philippines, Malaysia, and Vietnam. ASCO's Press Center highlighted the study ahead of ASCO Breakthrough 2026, noting the importance of evaluating multi-cancer early detection in routine clinical settings in Asia.
In an interim analysis of 22,597 individuals with at least 12 months of follow-up, SPOT-MAS demonstrated performance consistent with earlier prospective validation study (K-DETEK). Notably, the test effectively identified cancers that typically lack routine screening programs in the region, including stomach, liver, and nasopharyngeal cancers.
ASCO Expert Commentary
ASCO Expert Julian Hong, MD, MS, radiation oncologist at University of California, San Francisco (UCSF) discussed the study in ASCO's Science in Seconds segment. He highlighted the potential of SPOT-MAS in multi-cancer early detection while emphasizing the importance of continued research, responsible interpretation, and appropriate diagnostic follow-up.
The SPOT-MAS study was led by Dr. Dang Luu Hong Nguyen of the Medical Genetics Institute. Dr. Dang also received a Conquer Cancer Merit Award at ASCO Breakthrough 2026, recognizing the quality and scientific merit of the research submitted to an ASCO meeting.
"Asia has a fundamentally different cancer landscape from the populations in which other MCED tests have been validated. Liver, gastric, and nasopharyngeal cancers are highly prevalent in this region yet have no standard screening programs. To date, this is the largest real-world MCED cohort reported from any Asian population," said Dr. Dang Nguyen, following ASCO's media interview.
Why Asia-Led Evidence Matters
"Multi-cancer early detection is an area where evidence generation must reflect the populations and healthcare systems in which the technology will be used," said Prof. Herbert Ho Fung Loong of The Chinese University of Hong Kong. "Large-scale real-world data from Asian populations are particularly important given the distinct cancer epidemiology across the region. The ASCO press release highlighted that SPOT-MAS data contribute meaningfully to this evolving evidence base and demonstrate how Asia-originated innovation can be evaluated in a globally relevant context. The U.S. FDA Breakthrough Device Designation is also an important milestone for emerging technologies like SPOT-MAS 10. While it is not regulatory approval in the United States, it reflects the need for continued rigorous evaluation of Asia-based technologies that may address major unmet needs in cancer detection."
SPOT-MAS 10 is designed to detect cancer-associated signals from circulating cell-free DNA using a multi-omic approach that includes methylation and fragmentomic signatures supported by machine-learning analysis. The test is intended as a complementary screening approach and does not replace existing guideline-recommended cancer screening programs.
In May 2026, Gene Solutions announced that the U.S. Food and Drug Administration granted Breakthrough Device Designation to SPOT-MAS 10. The proposed intended use describes SPOT-MAS 10 as an adjunctive screening test for asymptomatic adults aged 40 years and older, designed to assist in detecting cancer-associated signals across cancer types within the scope of the assay.
Breakthrough Device Designation is not FDA approval, clearance, or marketing authorization, and SPOT-MAS 10 remains subject to applicable FDA review requirements.
About SPOT-MAS 10
SPOT-MAS 10 is an AI-powered, multi-omic blood-based test developed by Gene Solutions to detect cancer-associated signals from circulating cell-free DNA. The test integrates methylation and fragmentomic signatures using machine-learning-based analysis and is designed to support multi-cancer early detection across 10 cancer types. SPOT-MAS 10 is intended to complement, not replace, existing guideline-recommended screening programs. Positive results require physician-directed diagnostic follow-up.
For more information, visit www.genesolutions.com and follow the company on LinkedIn, Facebook, and X.
Contact: pr@genesolutions.com
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Gene Solutions' SPOT-MAS 10 Places Asia-Led Cancer Screening Innovation in the Global Spotlight
